Implications of the 5th Edition of the World Health Organization Classification and International Consensus Classification of Myeloid Neoplasm in Myelodysplastic Syndrome With Excess Blasts and Acute Myeloid Leukemia
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
The fifth edition of the WHO classification (2022 WHO) and the International Consensus Classification (2022 ICC) of myeloid neoplasms have been recently published. We reviewed the changes in the diagnosis distribution in patients with MDS with excess blasts (MDS-EB) or AML using both classifications. Forty-seven patients previously diagnosed as having AML or MDS-EB with available mutation analysis data, including targeted next-generation and RNA-sequencing data, were included. We reclassified 15 (31.9%) and 27 (57.4%) patients based on the 2022 WHO and 2022 ICC, respectively. One patient was reclassified as having a translocation categorized as a rare recurring translocation in both classifications. Reclassification was mostly due to the addition of mutation-based diagnostic criteria (i.e., AML, myelodysplasia-related) or a new entity associated with TP53 mutation. In both classifications, MDS diagnosis required the confirmation of multi-hit TP53 alterations. Among 14 patients with TP53 mutations, 11 harbored multi-hit TP53 alterations, including four with TP53 mutations and loss of heterozygosity. Adverse prognosis was associated with multi-hit TP53 alterations (P=0.009) in patients with MDS-EB, emphasizing the importance of detecting the mutations at diagnosis. The implementation of these classifications may lead to the identification of different subtypes from previously heterogeneous diagnostic categories based on genetic characteristics.
Abstract
The fifth edition of the WHO classification (2022 WHO) and the International Consensus Classification (2022 ICC) of myeloid neoplasms have been recently published. We reviewed the changes in the diagnosis distribution in patients with MDS with excess blasts (MDS-EB) or AML using both classifications. Forty-seven patients previously diagnosed as having AML or MDS-EB with available mutation analysis data, including targeted next-generation and RNA-sequencing data, were included. We reclassified 15 (31.9%) and 27 (57.4%) patients based on the 2022 WHO and 2022 ICC, respectively. One patient was reclassified as having a translocation categorized as a rare recurring translocation in both classifications. Reclassification was mostly due to the addition of mutation-based diagnostic criteria (i.e., AML, myelodysplasia-related) or a new entity associated with TP53 mutation. In both classifications, MDS diagnosis required the confirmation of multi-hit TP53 alterations. Among 14 patients with TP53 mutations, 11 harbored multi-hit TP53 alterations, including four with TP53 mutations and loss of heterozygosity. Adverse prognosis was associated with multi-hit TP53 alterations (P=0.009) in patients with MDS-EB, emphasizing the importance of detecting the mutations at diagnosis. The implementation of these classifications may lead to the identification of different subtypes from previously heterogeneous diagnostic categories based on genetic characteristics.
참고문헌 (15)
- Bernard E, "Molecular international prognostic scoring system for myelodysplastic syndromes", NEJM Evid, 1, pp.EVIDoa2200008~ (2022)
- Döhner H, "Diagnosis and management of AML in adults : 2022 recommendations from an international expert panel on behalf of the ELN", Blood, 140, pp.1345~1377 (2022)
- Cancer Genome Atlas Research Network, "Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia", N Engl J Med, 368, pp.2059~2074 (2013)
- Park Hee Sue, "Serial Analysis and Comparison of Mutation Profiles in Decitabine-treated Myeloid Sarcoma and Subsequent Acute Myeloid Leukemia Using Next-Generation Sequencing", Annals of Laboratory Medicine, 42(5), pp.602~605 (2022), 대한진단검사의학회[DOI]
- Khoury JD, "The 5th edition of the World Health Organization classification of haematolymphoid tumours : myeloid and histiocytic", dendritic neoplasms, 2022, pp.36, 1703~1719
- Arber DA, "International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data", Blood, 140, pp.1200~1228 (2022)
- Arber DA, "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia", Blood, 127, pp.2391~2405 (2016)
- McGowan-Jordan J, "ISCN 2020: An International System for Human Cytogenomic Nomenclature" (2020), Karger
- Dobin A, "STAR : ultrafast universal RNA-seq aligner", Bioinformatics, 29, pp.15~21 (2013)
- ". (2018). ESMO Open, 3(Suppl 2), A179" (2022)[URL]
- (2017)[URL]
- Bolouri H, "The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions", Nat Med, 24, pp.103~112 (2018)
- Bernard E, "Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes", Nat Med, 26, pp.1549~1556 (2020)
- Grob T, "Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome", Blood, 139, pp.2347~2354 (2022)
- Haase D, "TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups", Leukemia, 33, pp.1747~1758 (2019)